(a)
(b)
(c)
(d)
(e)
(f)
(g)
Figure 4: T-tau, TNF-α, and IL-1β protein levels in the CSF of AD patients measured by Western blot. Protein levels of T-tau (a), TNF-α (b) and IL-1β (c) from AD patients’ CSF, and (d) β-actin. 1: DON treatment group; 2: CH treatment group; 3: control group. For (e)–(g) the relative changes in protein content of T-tau, TNF-α, and IL-1β. The contents of T-tau, TNF-α, and IL-1β had decreased during 48 weeks compared with control group after drug treatments (). There was no statistical deviation between DON treatment group and CH treatment group ().